Seroatlas · Human Serome Atlas

SFT2D2

Vesicle transport protein SFT2B

Also known as: dJ747L4.C1.2, SFT2B_HUMAN, UNQ512

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
O95562
Gene
SFT2D2
Ensembl
ENSG00000213064
Chromosome
1
Canonical length
160 aa
Protein class
Predicted membrane proteins

OverviewNCBI Gene

Predicted to be involved in protein transport and vesicle-mediated transport. Located in extracellular exosome. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

160 residues, UniProt reviewed canonical sequence.

>O95562|SFT2D2
     1  MDKLKKVLSG QDTEDRSGLS EVVEASSLSW STRIKGFIAC FAIGILCSLL GTVLLWVPRK
    61  GLHLFAVFYT FGNIASIGST IFLMGPVKQL KRMFEPTRLI ATIMVLLCFA LTLCSAFWWH
   121  NKGLALIFCI LQSLALTWYS LSFIPFARDA VKKCFAVCLA

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against SFT2D2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Intracellular
Secreted
No
Transmembrane segments
4
Mean surface accessibility (rSASA)
0.35
Highest tissue expression
30 nTPM

Expression across tissuesHPA

Tissue

  • bone marrow: 30 nTPM
  • testis: 17 nTPM
  • endometrium: 16 nTPM
  • skin: 14 nTPM
  • ovary: 14 nTPM
  • blood vessel: 12 nTPM

Single-cell type

  • esophageal apical cells: 262 nCPM
  • late spermatids: 260 nCPM
  • corticotrophs: 246 nCPM
  • kupffer cells: 193 nCPM
  • pdcs: 171 nCPM
  • lactotrophs: 134 nCPM

Immune cell

  • plasmacytoid DC: 53 nTPM
  • non-classical monocyte: 28 nTPM
  • intermediate monocyte: 22 nTPM
  • basophil: 21 nTPM
  • myeloid DC: 17 nTPM
  • classical monocyte: 12 nTPM

Brain region

  • medulla oblongata: 51 nTPM
  • white matter: 50 nTPM
  • pons: 45 nTPM
  • hypothalamus: 44 nTPM
  • hippocampal formation: 43 nTPM
  • thalamus: 43 nTPM

ReferencesPubMed · IEDB

Publications for SFT2D2 from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.

Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
0.9
gnomAD pLI
0.01
gnomAD missense Z
-0.16
DepMap mean gene effect
-0.04
DepMap dependency class
selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 8% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads SFT2D2 as an antibody target. Whether an autoantibody or antibody against SFT2D2 could matter depends on whether native SFT2D2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

SFT2D2 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label SFT2D2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/SFT2D2. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

Loading the interactive Seroatlas protein explorer...